Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...

These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health conditions.

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...